| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
|
PF-04859989 HCl is a novel, selective, irreversible and brain-penetrant inhibitor of kynurenine amino transferase II (KAT II) with the potential for the treatment of cognitive impairment associated with schizophrenia and other psychiatric disorders. It is cyclic hydroxamic acid identified from a high-throughput screen. PF-04859989 acts by forming a covalent adduct with the enzyme cofactor, pyridoxal phosphate (PLP), in the active site. PF-04859989 is capable of reducing brain kynurenic acid by 50% at a dose of 10 mg/kg (sc).
| ln Vivo |
PF-04859989 is a brain-penetrating, irreversible inhibitor that decreases brain kynurenic acid by 50% at a dose of 10 mg/kg (sc) according to in vivo pharmacokinetic and effectiveness tests conducted in rats [1]. PF-04859989 (5 mg/kg; i.p.)-treated rats displayed a marked decrease in the quantity of spontaneously activated DA neurons per trajectory [1].
|
|---|---|
| Animal Protocol |
Animal/Disease Models: Male SD (SD (Sprague-Dawley)) rat [2]
Doses: 5 mg/kg Route of Administration: intraperitoneal (ip) injection Experimental Results: The number of spontaneously active dopamine (DA) neurons per track was Dramatically diminished compared with the control. |
| References |
|
| Molecular Formula |
C9H10N2O2.HCL
|
|---|---|
| Molecular Weight |
214.64884
|
| Exact Mass |
214.051
|
| CAS # |
177943-33-8
|
| Related CAS # |
56433-01-3 (PF-04859989); 177943-33-8 (PF-04859989 HCl);
|
| PubChem CID |
22868922
|
| Appearance |
White to off-white solid powder
|
| LogP |
1.859
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
0
|
| Heavy Atom Count |
14
|
| Complexity |
220
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
C1[C@@H](C(=O)N(C2=CC=CC=C21)O)N.Cl
|
| InChi Key |
WZOBDOKCHIUXAY-FJXQXJEOSA-N
|
| InChi Code |
InChI=1S/C9H10N2O2.ClH/c10-7-5-6-3-1-2-4-8(6)11(13)9(7)12;/h1-4,7,13H,5,10H2;1H/t7-;/m0./s1
|
| Chemical Name |
(3S)-3-amino-1-hydroxy-3,4-dihydroquinolin-2-one;hydrochloride
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O : ~100 mg/mL (~465.87 mM)
DMSO : ~20.83 mg/mL (~97.04 mM) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (11.65 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (11.65 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (11.65 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. Solubility in Formulation 4: 50 mg/mL (232.94 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with ultrasonication. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.6587 mL | 23.2937 mL | 46.5875 mL | |
| 5 mM | 0.9317 mL | 4.6587 mL | 9.3175 mL | |
| 10 mM | 0.4659 mL | 2.3294 mL | 4.6587 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
